## IN THE CLAIMS

Please delete all prior lists of claims in the application and insert the following list of claims:

- 1. [Cancel] An isolated polypeptide comprising in amino to carboxy order P4-P3-P2-P1, wherein P4 is P, P3 is R or K, P2 is any amino acid, and P1 is K or R (SEO. ID. NO: 1).
- 2. [Cancel] The isolated polypeptide of claim 1, wherein P4 is amino-terminally blocked.
- 3. [Cancel] The isolated polypeptide of claim 2, wherein P4 is acetylated.
- 4. [Currently Amended] The isolated polypeptide of claim 2, An isolated polypeptide comprising in amino to carboxy order P4-P3-P2-P1, wherein P4 is P, P3 is A or R or K, P2 is any amino acid, and P1 is K or R (SEQ. ID. NO: 1 and SEQ. ID. NO: 6), wherein P4 is amino-terminally blocked, and further comprising a fluorogenic leaving group that is covalently bound to P4-P3-P2-P1 at a carboxy-terminus of P4-P3-P2-P1.
- 5. [Original] The isolated polypeptide of claim 4, wherein the fluorogenic leaving group is bound via an amide bond.
- 6. [Original] The isolated polypeptide of claim 4, wherein the fluorogenic leaving group comprises 7-amino-4-carbamoylmethyl-coumarin.
- 7. [Currently Amended] The isolated polypeptide of claim † 4, wherein P2 is N and further comprising a fluorogenic leaving group that is bound to P4-P3-P2-P1 via an amide bond on a carboxy-terminus of P4-P3-P2-P1

- 8. [Original] The isolated polypeptide of claim 7, wherein the fluorogenic leaving group comprises 7-amino-4-carbamoylmethyl-coumarin.
- 9. [Original] The isolated polypeptide of claim 6, wherein P4-P3-P2-P1 is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7).
- 10. [Original] The isolated polypeptide of claim 9, wherein P4-P3-P2-P1 is P-R-N-K (SEQ. ID. NO: 2).
- 11. [Original] The isolated polypeptide of claim 9, wherein P4-P3-P2-P1 is P-K-N-K (SEQ. ID. NO: 3).
- 12. [Original] The isolated polypeptide of claim 9, wherein P4-P3-P2-P1 is P-R-N-R (SEQ. ID. NO: 4).
- 13. [Original] The isolated polypeptide of claim 9, wherein P4-P3-P2-P1 is P-K-N-R (SEQ. ID. NO: 5).
- 14. [Original] The isolated polypeptide of claim 9, wherein P4-P3-P2-P1 is P-A-N-K (SEQ. ID. NO: 6).
- 15. [Original] The isolated polypeptide of claim 9, wherein P4-P3-P2-P1 is P-R-T-K (SEQ. ID. NO: 7).
- 16. [Cancel] The isolated polypeptide of claim 1, wherein P1 is linked to a serine protease reactive inhibitor moiety.

- 17. [Cancel] The isolated polypeptide of claim 16, wherein the serine protease reactive inhibitor moiety is chloromethyl ketone, which is linked to P1.
- 18. [Cancel] The isolated polypeptide of claim 16, wherein P4 is amino-terminally blocked.
- 19. [Cancel] The isolated polypeptide of claim 18, wherein P4 is acetylated.
- 20. [Cancel] The isolated polypeptide of claim 18, wherein P2 is N.
- 21. [Cancel] The isolated polypeptide of claim 20, wherein P4-P3-P2-P1 is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7).
- 22. [Cancel] The isolated polypeptide of claim 21, wherein P4-P3-P2-P1 is P-R-N-K (SEQ. ID. NO: 2).
- 23. [Cancel] The isolated polypeptide of claim 21, wherein P4-P3-P2-P1 is P-K-N-K (SEQ. ID. NO: 3).
- 24. [Cancel] The isolated polypeptide of claim 21, wherein P4-P3-P2-P1 is P-R-N-R (SEQ. ID. NO: 4).
- 25. [Cancel] The isolated polypeptide of claim 21, wherein P4-P3-P2-P1 is P-K-N-R (SEQ: ID. NO: 5).
- 26. [Cancel] The isolated polypeptide of claim 21, wherein P4-P3-P2-P1 is P-A-N-K (SEQ. ID. NO: 6).

- 27. [Cancel] The isolated polypeptide of claim 21, wherein P4-P3-P2-P1 is P-R-T-K (SEQ. ID. NO: 7).
- 28. [Original] A method of assaying activity of an enzymatically-active β-tryptase in a sample, the method comprising:
  - (a) contacting the sample with an isolated polypeptide comprising in amino to carboxy order P4-P3-P2-P1, wherein P4 is amino-terminally blocked and is P, and wherein P4-P3-P2-P1 is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7), and further wherein a fluorogenic leaving group comprising 7-amino-4-carbamoylmethyl-coumarin is bound via an amide bond to P4-P3-P2-P1 at a carboxy-terminus of P4-P3-P2-P1, under conditions wherein an amount of the fluorogenic leaving group is cleaved from P4-P3-P2-P1 upon action of the β-tryptase, thereby producing a fluorescent moiety; and then
  - (b) quantifying the amount of detectable leaving group cleaved from the polypeptide, the amount being an indication of the activity of the enzymatically-active  $\beta$ -tryptase in the sample.
- 29. [Original] The method of claim 28, wherein in step (a), the detectable leaving group is a fluorogenic leaving group.
- 30. [Original] The method of claim 29, wherein in step (a), the fluorogenic leaving group is attached to a carboxy-terminus of P4-P3-P2-P1 via an amide bond.
- 31. [Original] The method of claim 29, wherein in step (a), P4 is acetylated.

- 32. [Original] The method of claim 31, wherein in step (b), the amount of detectable leaving group cleaved from the polypeptide is detected by observing whether the sample undergoes a detectable change in fluorescence.
- 33. [Original] The method of claim 28, wherein the sample is a bodily fluid clinical sample.
- 34. [Original] The method of claim 33, wherein the clinical sample is whole blood, serum, plasma, urine, tears, lavage, tissue extract, or conditioned media.
- 35. [Original] The method of claim 28, further comprising, prior to step (a), adding aprotinin to the sample to inhibit proteases other than β-tryptase, thereby reducing non-specific cleavage of the detectable leaving group from P4-P3-P2-P1 by proteases other than β-tryptase.
- 36. [Original] A method of assaying activity of an enzymatically-active β-tryptase in a sample, the method comprising:
  - (a) contacting the sample with an isolated polypeptide comprising in amino to carboxy order P4-P3-P2-P1, wherein P4 is amino-terminally blocked, and wherein P4-P3-P2-P1 is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7), and further wherein a fluorogenic leaving group comprising 7-amino-4-carbamoylmethyl- coumarin is bound via an amide bond to P4-P3-P2-P1 at a carboxy-terminus of P4-P3-P2-P1, under conditions wherein an amount of the fluorogenic leaving group is cleaved from P4-P3-P2-P1 upon action of the β-tryptase, thereby producing a fluorescent moiety; and then

- (b) measuring whether the sample undergoes a detectable change in fluorescence, the detectable change being an indication of the activity of the enzymatically-active  $\beta$ -tryptase in the sample.
- 37. [Original] The method of claim 34, further comprising adding aprotinin to the sample to inhibit proteases other than  $\beta$ -tryptase, thereby reducing non-specific cleaveage of the fluorogenic leaving group from P4-P3-P2-P1 by proteases other than  $\beta$ -tryptase.
- 38. [Cancel] A method of inhibiting an enzymatically-active β-tryptase in a sample, the method comprising: contacting the sample with an isolated polypeptide comprising in amino to carboxy order P4-P3-P2-P1, wherein P4 is P, P3 is R or K, P2 is any amino acid, and P1 is K or R (SEQ. ID. NO: 1), wherein P4 is acetylated, and wherein P1 is linked to a chloromethyl ketone, under conditions wherein the isolated polypeptide interacts with and inhibits enzymatic β-tryptase present in the sample.
- 39. [Cancel] The method of claim 38, further comprising quantifying inhibition of the β-tryptase activity in the sample.
- 40. [Cancel] The method of claim 38, wherein in step (a), P4-P3-P2-P1 is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7).
- 41. [Currently Amended] A kit for analyzing samples for  $\beta$ -tryptase activity comprising:

an isolated polypeptide comprising in amino to carboxy order P4-P3-P2-P1, wherein P4 is P, P3 is A or R or K, P2 is any amino acid, and P1 is K or

- R (SEQ. ID. NO: 1 and SEQ. ID. NO: 6), and wherein a one and only one detectable leaving group is covalently bound to P4-P3-P2-P1; and a suitable container, the isolated polypeptide being disposed therein.
- 42. [Original] The kit of claim 41, wherein the isolated polypeptide is provided in solution, lyophilized, or bound to a solid support.

, #

- 43. [Cancel] The kit of claim 41, wherein P4-P3-P2-P1 further comprises a serine protease reactive moiety.
- 44. [Original] The kit of claim 41, wherein P4 of the isolated polypeptide is acetylated.
- 45. [Original] The kit of claim 41, wherein the detectable leaving group is a fluorogenic leaving group covalently bonded to a carboxy-terminus of P4-P3-P2-P1 via an amide bond.
- 46. [Original] The kit of claim 41, wherein P4-P3-P2-P1 is selected from the group consisting of P-R-N-K (SEQ. ID. NO: 2), P-K-N-K (SEQ. ID. NO: 3), P-R-N-R (SEQ. ID. NO: 4), P-K-N-R (SEQ. ID. NO: 5), P-A-N-K (SEQ. ID. NO: 6), and P-R-T-K (SEQ. ID. NO: 7).
- 47. [Original] The kit of claim 41, further comprising a supply of aprotinin disposed in a second container.
- 48. [Cancel] The kit of claim 41, wherein p1 is linked to a chloromethyl ketone.